The overexpression of PSMA in prostate cancer has been well documented, which has been widely applied, as a molecular target, in the clinical diagnosis and treatment of prostate cancer and exhibited extremely high sensitivity and performance. The gene discussed is FOLH1; the disease is prostate carcinoma.